ChemoCentryx, Inc.

2014 Q2 Form 10-Q Financial Statement

#000119312514192166 Filed on May 09, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $99.90M $132.6M $75.90M
YoY Change -23.04% 74.7% -36.49%
Cash & Equivalents $13.11M $11.63M $11.64M
Short-Term Investments $86.80M $120.9M $64.30M
Other Short-Term Assets $900.0K $1.100M $900.0K
YoY Change -10.0% 22.22% -40.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $900.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $100.8M $133.7M $77.80M
YoY Change -23.44% 71.83% -35.97%
LONG-TERM ASSETS
Property, Plant & Equipment $1.241M $1.278M $1.300M
YoY Change 1.72% -1.69% -7.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $33.30M $9.300M $33.80M
YoY Change -9.02% -72.49% 24.72%
Other Assets $182.0K $160.0K $300.0K
YoY Change 13.75% -46.67% 50.0%
Total Long-Term Assets $34.75M $10.77M $35.40M
YoY Change -8.53% -69.56% 23.78%
TOTAL ASSETS
Total Short-Term Assets $100.8M $133.7M $77.80M
Total Long-Term Assets $34.75M $10.77M $35.40M
Total Assets $135.5M $144.5M $113.2M
YoY Change -20.11% 27.62% -24.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $690.0K $710.0K $800.0K
YoY Change -42.4% -11.25% -50.0%
Accrued Expenses $7.130M $6.187M $5.400M
YoY Change 28.63% 14.57% 54.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $200.0K $500.0K
YoY Change -80.0% -60.0% 0.0%
Total Short-Term Liabilities $7.925M $7.081M $9.400M
YoY Change -9.24% -24.67% -6.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $200.0K
YoY Change -100.0% -100.0% -75.0%
Other Long-Term Liabilities $192.0K $195.0K $300.0K
YoY Change -20.0% -35.0% -89.29%
Total Long-Term Liabilities $192.0K $195.0K $500.0K
YoY Change -20.0% -61.0% -86.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.925M $7.081M $9.400M
Total Long-Term Liabilities $192.0K $195.0K $500.0K
Total Liabilities $8.117M $7.276M $9.900M
YoY Change -10.83% -26.51% -27.74%
SHAREHOLDERS EQUITY
Retained Earnings -$196.7M -$184.4M
YoY Change 27.8%
Common Stock $43.00K $43.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $127.4M $137.2M $103.3M
YoY Change
Total Liabilities & Shareholders Equity $135.5M $144.5M $113.2M
YoY Change -20.11% 27.62% -24.58%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43252383 shares
CY2013Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.00
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11637000
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43172171 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43172171 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.21
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7134142 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1967397 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1700000 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6187000
CY2014Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
321499000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
710000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7081000
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
58000
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
195000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
137185000
CY2014Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2014Q1 us-gaap Secured Debt Current
SecuredDebtCurrent
184000
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184399000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
43000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
144461000
CY2014Q1 us-gaap Liabilities
Liabilities
7276000
CY2014Q1 us-gaap Long Term Investments
LongTermInvestments
9336000
CY2014Q1 us-gaap Assets Current
AssetsCurrent
133687000
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160000
CY2014Q1 us-gaap Assets
Assets
144461000
CY2014Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
140322000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11628000
CY2014Q1 us-gaap Short Term Investments
ShortTermInvestments
120945000
CY2014Q1 us-gaap Available For Sale Securities And Held To Maturity Securities
AvailableForSaleSecuritiesAndHeldToMaturitySecurities
0
CY2014Q1 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
4000
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1110000
CY2014Q1 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2014Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
140263000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4429264
CY2014Q1 us-gaap Cash
Cash
1600000
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
19200000
CY2014Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10041000
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1278000
CY2014Q1 ccxi Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
-12000
CY2014Q1 ccxi Available For Sale Securities Gross Unrealized Gain Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedInInvestments
0
CY2014Q1 ccxi Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
71000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8460000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42888168 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42888168 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.71
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5301622 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2383920 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5649000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
318103000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
909000
CY2013Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
16000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6872000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
40000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
226000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
145308000
CY2013Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
314000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172862000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152422000
CY2013Q4 us-gaap Liabilities
Liabilities
7114000
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
16561000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
134302000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160000
CY2013Q4 us-gaap Assets
Assets
152422000
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
147828000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10258000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
123055000
CY2013Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
393000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
596000
CY2013Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
16000
CY2013Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
147788000
CY2013Q4 us-gaap Cash
Cash
2000000
CY2013Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8212000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1399000
CY2013Q4 ccxi Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
-26000
CY2013Q4 ccxi Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
66000
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000 shares
CY2013Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64400000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36611000 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10266000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5121444 shares
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
312000
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-222000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10202000
CY2013Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1927000
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
116000
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
127000
CY2013Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-9000
CY2013Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
141000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10292000
CY2013Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
36682000
CY2013Q1 us-gaap Interest Paid
InterestPaid
9000
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
99000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-10193000
CY2013Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
12219000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2964000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1464000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1128000
CY2013Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
312000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1536000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3177000
CY2013Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
11979000
CY2013Q1 us-gaap Interest Expense
InterestExpense
17000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9255000
CY2013Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2013Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-846000
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1293000
CY2013Q1 us-gaap Depreciation
Depreciation
142000
CY2013Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
48697000
CY2013Q1 ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
-409000
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
ChemoCentryx, Inc.
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
18000
CY2014Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
146000
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001340652
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2279800 shares
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-389000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11519000
CY2014Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
146000
CY2014Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Description of Business</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally administered chemokine-based therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company&#x2019;s principal operations are in the United States and it operates in one segment.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Unaudited Interim Financial Information</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December&#xA0;31, 2013 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (GAAP). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company&#x2019;s financial statements and the notes thereto included in the Company&#x2019;s annual report on Form 10-K for the year ended December&#xA0;31, 2013 filed with the Securities and Exchange Commission, or SEC, on March&#xA0;14, 2014.</p> </div>
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M4D
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43107000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.63
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8461000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11672000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.54
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2279800 shares
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M19D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
163277 shares
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
284003 shares
CY2014Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Reclassifications</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain items in the notes to Condensed Consolidated Financial Statements have been reclassified to conform to the current fiscal year&#x2019;s format.</p> </div>
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.55
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7340380 shares
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.</p> </div>
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
514000
CY2014Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
33000000
CY2014Q1 us-gaap Interest Paid
InterestPaid
3000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
135000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-11537000
CY2014Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
11672000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3523000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1144000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2106000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1370000
CY2014Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8687000
CY2014Q1 us-gaap Interest Expense
InterestExpense
11000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-199000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8149000
CY2014Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2014Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
499000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1290000
CY2014Q1 us-gaap Depreciation
Depreciation
153000
CY2014Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
41719000
CY2014Q1 ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Option Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionForfeited
163277 shares
CY2014Q1 ccxi Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
0 shares
CY2014Q1 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized
shares
CY2014Q1 ccxi Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
shares
CY2014Q1 ccxi Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
-642000
CY2014Q1 ccxi Share Based Compensation Arrangement By Share Based Payment Award Options Shares Authorized Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAuthorizedWeightedAverageExercisePrice

Files In Submission

Name View Source Status
0001193125-14-192166-index-headers.html Edgar Link pending
0001193125-14-192166-index.html Edgar Link pending
0001193125-14-192166.txt Edgar Link pending
0001193125-14-192166-xbrl.zip Edgar Link pending
ccxi-20140331.xml Edgar Link completed
ccxi-20140331.xsd Edgar Link pending
ccxi-20140331_cal.xml Edgar Link unprocessable
ccxi-20140331_def.xml Edgar Link unprocessable
ccxi-20140331_lab.xml Edgar Link unprocessable
ccxi-20140331_pre.xml Edgar Link unprocessable
d701281d10q.htm Edgar Link pending
d701281dex311.htm Edgar Link pending
d701281dex312.htm Edgar Link pending
d701281dex321.htm Edgar Link pending
d701281dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending